Prognostic value of FDG PET/CT in head and neck squamous cell carcinomas

D Dequanter1,2
M Shahla2
C Aubert2
Y Deniz2
P Lothaire2

1Department of Oncology, Laboratory of Experimental Radiotherapy, KU Leuven, Leuven, Belgium; 2Head and Neck Department, Hôpital André Vésale, CHU de Charleroi, Montigny le Tilleul, Belgium

Introduction: The purpose of this study was to evaluate the use of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) to identify the presence of cervical lymph nodes metastases and extracapsular spread with histologic correlations in head and neck squamous cell carcinoma.

Methods: The medical records of 54 patients who underwent 18F-FDG PET/CT for head and neck squamous cell carcinoma before surgery were reviewed. Receiver operating characteristic (ROC) analysis was performed to differentiate patients with cervical lymph node metastasis from those without lymph node metastasis. The same statistical analysis was done to differentiate cervical lymph nodes with extracapsular spread from those without extracapsular spread.

Results: Metastatic disease was diagnosed histologically in 49% (26 of 54) of the patients. Extracapsular spread was present in ten of the 54 patients (19%). When ROC curve analysis and maximum standardized uptake (SUVmax) values were used to detect cervical lymph node metastasis, the area under the ROC curve was 0.96 and the optimal cutoff value for SUVmax was 4.05 based on ROC curve analysis. The sensitivity and specificity of SUVmax for the detection of cervical lymph node metastasis using this cutoff point were 92% and 88%, respectively. When ROC curve analysis and SUVmax values were used in order to detect extracapsular spread, the area under the ROC curve was 0.86, and the optimal cutoff value for SUVmax was 4.15 based on ROC curve analysis. Using this cutoff value, the sensitivity and specificity of SUVmax for the detection of extracapsular spread were 83% and 88%, respectively.

Conclusion: In our study, a median 18F-FDG PET/CT SUVmax cutoff value of 4.15 was found to be related with cervical lymph node metastasis and extracapsular spread in patients with head and neck cancer.

Keywords: maximum standardized uptake value, PET/CT, head and neck cancer, lymph node metastases, extracapsular spread

Introduction

Many variables have been implicated in the prognosis of patients with head and neck cancer, but the presence of cervical lymph node metastasis, eventually associated with extracapsular spread, remains the most significant prognostic factor in terms of recurrence of cancer and survival of these patients. The presence of lymph node metastasis and, certainly, the presence of extracapsular spread reduce the 5-year survival rate by about 50%.1

Nowadays, positron emission tomography/computed tomography (PET/CT) using 18F-fluorodeoxyglucose (FDG) is being increasingly carried out for the staging and localization of metastatic disease in patients with head and neck cancer. It has been reported to be superior to conventional imaging for the evaluation of patients with head and neck malignancies and to have a sensitivity of 77%–96% and a specificity of 82%–100% for the detection of cervical lymph node metastases from head and neck cancer.
neck cancers.\textsuperscript{1-2} Indeed, the sensitivity of CT for diagnosis of cervical lymph node metastasis is about 81% and its specificity about 72%, whereas the sensitivity and specificity of magnetic resonance imaging (MRI) range from 57% to 77% and 57% to 72%, respectively.\textsuperscript{3} The sensitivity and specificity of ultrasound in detecting cervical node metastasis were 81.4% and 64.2%, respectively.\textsuperscript{4}

The purpose of this study was to assess the value of \textsuperscript{18}F-FDG PET/CT for determining the presence of cervical lymph node metastases and extracapsular spread in head and neck squamous cell carcinoma (HNSCC) and to identify its histologic correlates.

**Methods**

In this retrospective study, the medical charts of patients who were treated initially by surgery and who underwent FDG PET/CT before surgery were retrieved and reviewed. Hospital approval was obtained for this study. All the patients had histologically proven head and neck cancer and no radiological evidence of distant metastasis at the time of presentation. Patients with non-squamous-cell carcinoma, an unresectable tumor, distant metastasis, a history of prior head and neck cancer, and those who had previously undergone neck surgery or chemoradiotherapy were excluded.

The diagnostic evaluations at presentation included a complete physical examination, panendoscopy, CT and/or an MRI scan of the head and neck, and FDG PET/CT. All the patients underwent neck dissection at the time of primary surgery, unilaterally in 32 cases and bilaterally in 22 cases.

The FDG PET/CT images that determine regional lymph node and extracapsular spread status were reassessed. Pathologic lymph node metastases were recorded using the neck-level system of the imaging-based nodal classification. In each patient, the largest lymph node (based on maximum axial diameter) at the cervical level was used to determine the lymph node diameter. Maximal axial diameter was defined as the greatest dimension observed for all the lymph nodes on axial CT images, and measured using a mouse-controlled cursor. Patients were staged according to the 2002 American Joint Committee on Cancer (AJCC) staging system.

All the patients fasted for at least 6 hours before the PET/CT study. \textsuperscript{18}F-FDG was injected intravenously (370–555 MBq) and scanning began 60 minutes later. No patients had a blood glucose level exceeding 130 mg/dL before \textsuperscript{18}F-FDG injection, and no intravenous contrast agent was administered.

If \textsuperscript{18}F-FDG uptake was perceptible in a certain lymph node, the case was deemed positive for metastasis, and conversely, if no \textsuperscript{18}F-FDG uptake was observed in the region, the case was regarded as free of cervical lymph node metastasis. For semiquantitative analysis, \textsuperscript{18}F-FDG maximum standardized uptake (SUV_{max}) values were measured by visually placing regions of interest around cervical lymph nodes with perceptible \textsuperscript{18}F-FDG uptake. If multiple nodes showed perceptible uptake, the node with the highest SUV_{max} value was selected. All PET/CT results were compared with postoperative pathology results.

Receiver operating characteristic (ROC) analysis was performed to differentiate patients with cervical lymph node metastasis from those without lymph node metastasis. The same statistical analysis was done to differentiate cervical lymph nodes with extracapsular spread from those without extracapsular spread.

**Results**

Patient characteristics are given in Table 1. In the first group of patients with lymph node metastasis with extracapsular spread, the median age was 51 years. In the second group of patients with cervical lymph node metastasis with extracapsular spread, the median age was 59 years. The median age was 54 years in the group of patients with no cervical lymph node metastasis. In our study, most of the patients were men. Concerning the primary site localization, \textsuperscript{18}F-FDG PET/CT showed that the primary site was mostly the larynx in the first group of patients. In patients with cervical lymph node metastasis without extracapsular spread, \textsuperscript{18}F-FDG PET/CT showed that the primary tumor site was mostly the pharynx. \textsuperscript{18}F-FDG PET/CT located the tumor equally in the buccal area and at the larynx in the last group of patients (Table 2).

Pathological stages T2 and T4 were identified in 10% and 90% of the patients in the first group. In the second group of patients, most of the tumors were at stage T4. About 71% of the patients in the last group presented a lesion at stage T4 (Table 3).

The tumor was well or moderately differentiated in most of the cases. The mean tumor volume was 58±24 mm (range: 29–66; 95% confidence interval).

<table>
<thead>
<tr>
<th>Table 1 Patient characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parameter</td>
</tr>
<tr>
<td>Median age (years)</td>
</tr>
<tr>
<td>Sex</td>
</tr>
<tr>
<td>Male (%)</td>
</tr>
<tr>
<td>Female (%)</td>
</tr>
</tbody>
</table>

**Abbreviations:** ECS, extracapsular spread; pN\textsuperscript{+}, patients with lymph node positive metastasis; pN\textsuperscript{−}, patients without lymph node metastasis.
A total of 54 patients underwent cervical dissection, and 304 measures of cervical levels (I–V) were included in the analysis undertaken to identify the relationship between $^{18}$F-FDG PET/CT and histological findings. Metastatic disease was diagnosed histologically in 26 (49%) of the 54 patients. Extracapsular spread was present in 10 of the 54 patients (19%). The median nodal SUV$_{max}$ was 3.34 ± 3.07 (range, 1.0–20.4; 95% confidence interval) in patients with lymph node metastasis without extracapsular spread. In patients with lymph node metastasis and extracapsular spread, the median nodal SUV$_{max}$ was 4.16 ± 2.45 (range, 1.25–18.4; 95% confidence interval).

When ROC curve analysis and SUV$_{max}$ values were used to detect cervical lymph node metastasis, the area under the ROC curve was 0.96 and the optimal cutoff value for SUV$_{max}$ was 4.05 based on ROC curve analysis. The sensitivity and specificity of SUV$_{max}$ for the detection of cervical lymph node metastasis using this cutoff point were 92% and 88%, respectively (Figure 1).

When ROC curve analysis and SUV$_{max}$ values were used to detect extracapsular spread, the area under the ROC curve was 0.86, and the optimal cutoff value for SUV$_{max}$ was 4.15 based on ROC curve analysis. Using this cutoff value, the sensitivity and specificity of SUV$_{max}$ for the detection of extracapsular spread were 83% and 88%, respectively (Figure 2).

**Discussion**

Nodal staging is critically important for the adequate treatment of HNSCCs because the presence of cervical lymph node metastases significantly reduces survival. Furthermore, the presence of extracapsular spread in metastatic disease increases the local recurrence rate by 3.5-fold as compared with oral squamous cell carcinoma without nodal metastasis or metastatic adenopathy without extracapsular spread.

At present, neck dissection with a histological examination is the most reliable means of diagnosing cervical lymph nodes metastasis and extracapsular spread, and it provides important prognostic information. There is a need for a noninvasive procedure that provides prognostic information of the same standard as histopathology.

Nowadays, $^{18}$F-FDG PET/CT SUV values are being increasingly carried out for staging and localization of nodal metastases.
metastatic disease, and for studying tumor aggressiveness in patients with head and neck cancer.2,3,5–9

This study was undertaken to assess the value of 18F-FDG PET/CT for determining the presence of cervical lymph node metastasis and extracapsular spread in head and neck cancer and to identify its histologic correlates.

In their study, Joo et al18 demonstrated that an optimum FDG PET/CT SUV\textsubscript{max} value of 2.25 effectively predicts the presence of extracapsular spread of cancer from the cervical lymph node with a sensitivity of 85% and a specificity of 88%.

Furthermore, the study provides evidence that, in addition to lymph node metastasis and extracapsular spread, a median 18F-FDG PET/CT SUV\textsubscript{max} value of >3.0 significantly predicts poor 5-year disease specific survival. In their study, 24 of the 26 patients (92%) with median 18F-FDG PET/CT SUV\textsubscript{max} of >3.0 had extracapsular spread.

Consistent with the prior reports,7,8 the present results showed that an 18F-FDG PET/CT SUV\textsubscript{max} of 4.05 was determined to predict the presence of cervical lymph nodes metastases correctly, with a sensitivity of 92% and a specificity of 88%.

Moreover, an 18F-FDG PET/CT SUV\textsubscript{max} value of 4.15 was found to predict the presence of extracapsular spread of cervical lymph node with a sensitivity of 83% and a specificity of 88%.

In their study, Kato et al11 demonstrated that the same SUV\textsubscript{max} value with a cutoff of 4.1 was found to be an independent predictive factor, after multivariate analysis, for overall survival.

In their series, Yu et al11 found a lower optimal SUV\textsubscript{max} of 2.36, at which the sensitivity and specificity was 76% for detecting lymph node metastases. The area under the ROC curve was 0.9017.

Lymph node metastases occurred in 21 lymph node groups among the 144 specimens taken from the 16 patients considered. Moreover, data from the literature showed that SUV\textsubscript{max} value could be a significant prognostic factor for overall survival.12,13

However, Kim et al14 in their retrospective study that identified 54 patients with surgically resected esophageal cancer who received 18F-FDG PET/CT, did not validate the prognostic value of SUV\textsubscript{max} for regional lymph node metastasis and overall survival.

In conclusion, in our study, a median 18F-FDG PET/CT SUV\textsubscript{max} cutoff value of 4.15 was found to be related with cervical lymph node metastasis and extracapsular spread in patients with head and neck cancer, which indicates that SUV\textsubscript{max} could be used as predictor of extracapsular spread, but, at this time and with regard to the literature, SUV\textsubscript{max} value did not provide prognostic information of the same standard as histology.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


Prognostic value of FDG PET/CT in HNSCC

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal